Quarterly report pursuant to Section 13 or 15(d)

Revenue Recognition - Disaggregation of Revenue (Details)

v3.19.3
Revenue Recognition - Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Disaggregation of Revenue [Line Items]        
Total revenues $ 21,906 $ 16,946 $ 49,808 $ 44,526
Americas [Member]        
Disaggregation of Revenue [Line Items]        
Total revenues 2,706 4,315 9,620 13,968
EMEA [Member]        
Disaggregation of Revenue [Line Items]        
Total revenues 12,205 6,274 24,672 15,075
APAC [Member]        
Disaggregation of Revenue [Line Items]        
Total revenues 6,995 6,357 15,516 15,483
Product Sales [Member]        
Disaggregation of Revenue [Line Items]        
Total revenues 10,351 8,405 24,588 18,291
Research and Development Revenue [Member]        
Disaggregation of Revenue [Line Items]        
Total revenues 11,555 8,541 25,220 26,235
Performance Enzymes [Member]        
Disaggregation of Revenue [Line Items]        
Total revenues 20,424 12,125 41,100 34,019
Performance Enzymes [Member] | Americas [Member]        
Disaggregation of Revenue [Line Items]        
Total revenues 2,706 4,315 9,620 13,968
Performance Enzymes [Member] | EMEA [Member]        
Disaggregation of Revenue [Line Items]        
Total revenues 10,723 1,453 15,964 4,568
Performance Enzymes [Member] | APAC [Member]        
Disaggregation of Revenue [Line Items]        
Total revenues 6,995 6,357 15,516 15,483
Performance Enzymes [Member] | Product Sales [Member]        
Disaggregation of Revenue [Line Items]        
Total revenues 10,351 8,405 24,588 18,291
Performance Enzymes [Member] | Research and Development Revenue [Member]        
Disaggregation of Revenue [Line Items]        
Total revenues 10,073 3,720 16,512 15,728
Novel Biotherapeutics [Member]        
Disaggregation of Revenue [Line Items]        
Total revenues 1,482 4,821 8,708 10,507
Novel Biotherapeutics [Member] | EMEA [Member]        
Disaggregation of Revenue [Line Items]        
Total revenues 1,482 4,821 8,708 10,507
Novel Biotherapeutics [Member] | Research and Development Revenue [Member]        
Disaggregation of Revenue [Line Items]        
Total revenues $ 1,482 $ 4,821 $ 8,708 $ 10,507